ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFN-γ production by mouse activated T lymphocytes

Inhibition of phosphodiesterase 7A ameliorates Concanavalin A-induced hepatitis in mice

“…an antisense oligonucleotide specific for PDE7A inhibits T cell activation [13]. PDE7A inhibition results in inhibition of the function of cytotoxic T lymphocytes [25] and activated T cells [15]. As CD4+ T cells, like NKT cells, played a crucial role in the induction of Con A-induced hepatitis model [3], suppression of T cell function might also contribute to the effect of PDE7A inhibitor on hepatitis in this study.…”

“…However, the study with the PDE7A-deficiet mice has demonstrated that PDE7A might not be necessary for the activation of T cells [14]. In this respect, it should be noted that PDE7A inhibitors impair cytokine production by T cells [15] and NKT cells [16].…”

Lack of involvement of type 7 phosphodiesterase in an experimental model of asthma

“…The PDE7A sub-type is predominantly expressed and functional in lymphocytes [16,17]. The role of PDE7B is still poorly described, but despite controversy about its role in lymphoid cells [13,14], its expression in thymus, bone marrow, neutrophil, epithelial cells and lungs [18,19] may support its involvement in pulmonary diseases.…”

cAMP‐Specific Phosphodiesterases: Modulation, Inhibition, and Activation

“…Both effects were mediated by increases in intracellular cAMP linked to the inhibition of PDE7A. Additionally, a related study found that ASB16165 also blocks IL2-induced INFg production in activated T cells, further demonstrating the role of PDE7 in the regulation of T-cell function [152]. The most recent study of PDE7 inhibition utilized a fission yeast-based growth assay to develop a highthroughput inhibitor screen [153].…”